Celldex Therapeutics, Inc.

CLDX

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0000744218

SEC filings (opens in a new tab)

No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Celldex Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of CLDX: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Of which not filed for Q4 2023	Q4 2023	Change
Holders	144	1	164	+21
Shares	50.6M	48.1K	61.0M	+10.5M (+20.7%)
Value	$1.39B	$1.32M	$2.42B	+$1.03B (+74.0%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (33)

Institutions that held Celldex Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to CLDX in Q4 2023
Institution	Shares	Value	% of portfolio
Baker Bros. Advisors LP	247,644	$9.82M	0.11%
Silverarc Capital Management, LLC	247,215	$9.80M	3.02%
Laurion Capital Management LP	138,531	$5.49M	0.20%
Schonfeld Strategic Advisors LLC	130,542	$5.18M	0.04%
Exome Asset Management LLC	111,300	$4.41M	4.36%
Monashee Investment Management LLC	100,209	$3.97M	0.70%
OrbiMed Advisors LLC	58,800	$2.33M	0.05%
Schroder Investment Management Group	48,099	$1.91M	0.00%
Atom Investors LP	40,882	$1.62M	0.29%
PFM Health Sciences, LP	35,000	$1.39M	0.08%
Trexquant Investment LP	31,429	$1.25M	0.03%
Prelude Capital Management, LLC	26,512	$1.05M	0.09%
DekaBank Deutsche Girozentrale	25,000	$994.0K	0.00%
Squarepoint Ops LLC	17,554	$696.2K	0.00%
Capstone Investment Advisors, LLC	12,653	$501.8K	0.01%
First Trust Advisors LP	11,563	$458.6K	0.00%
NEOS Investment Management LLC	11,560	$458.5K	0.04%
Fox Run Management, L.L.C.	11,249	$446.1K	0.11%
Handelsbanken Fonder AB	8,100	$321.0K	0.00%
ProShare Advisors LLC	7,690	$305.0K	0.00%
Values First Advisors, Inc.	7,399	$293.4K	0.18%
Victory Capital Management Inc	7,252	$287.6K	0.00%
Panoramic Investment Advisors, LLC	6,500	$257.8K	0.22%
Aigen Investment Management, LP	6,327	$250.9K	0.04%
Wolverine Trading, LLC	5,058	$200.6K	0.00%
BIT Capital GmbH	4,313	$171.1K	0.02%
Aquatic Capital Management LLC	3,400	$135.0K	0.00%
Lindbrook Capital, LLC	155	$6.15K	0.00%
Signaturefd, LLC	113	$4.48K	0.00%
EverSource Wealth Advisors, LLC	39	$1.55K	0.00%
Livelsberger Financial Advisory	33	$1.31K	0.00%
Scarborough Advisors, LLC	6	$238	0.00%
Strategic Investment Solutions, Inc.	5	$198	0.00%

Sold out (12)

Institutions that held Celldex Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of CLDX in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
Gsa Capital Partners LLP	44,716	$1.23M
ExodusPoint Capital Management, LP	26,434	$727.0K
HighVista Strategies LLC	17,482	$481.1K
Los Angeles Capital Management LLC	16,082	$442.6K
AlphaCentric Advisors LLC	15,000	$412.8K
XTX Topco Ltd	11,159	$307.1K
Centiva Capital, LP	9,727	$267.7K
Allspring Global Investments Holdings, LLC	1,941	$53.4K
North Star Investment Management Corp.	800	$22.0K
Headlands Technologies LLC	718	$19.8K
Byrne Asset Management LLC	86	$2.00K
Bogart Wealth, LLC	15	$413

Not filed for Q4 2023 yet (1)

Institutions that held Celldex Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CLDX in Q3 2023 that haven't filed for Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
International Biotechnology Trust PLC	48,099	$1.32M